Health
CAR-T Therapy Safety Concerns Emerge
A patient died in a Bristol Myers Squibb autoimmune CAR-T trial, raising questions about the safety bar for such therapies. A separate analysis found that most new cancer drugs approved by European regulators do not offer high clinical benefit.
Coverage timeline — 2 articles
STAT News
Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
2026-10-23 18:48 UTC
STAT News
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
2026-10-23 18:55 UTC